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stent to artery ratio 1 .l :I .O to 1.2:l .O, and were subjected to gamma-radiation using ‘92ir. 
The prescribed doses were 0 Gy (controls), 15 Gy, or 30 Gy at 2 mm from the center of 
the swrce axis. Animals were sacrificed at 1, 3, and 6 months and arteries were ana- 
lyzed for histomorphometry (n=36) or scanning electron microscopy (n=36). lntimal area 
(IA) was reduced after VBT at 3 months with 15 Gy and 30 Gy es compared to controls 
and at 6 months with 30 Gy (Table). There was no difference in IA at 6 months between 
15 Gy and controls. The surface covered by endothelium was reduced in radiated arter- 
ies at all time points and did not increase from 1 to 6 months. Excess of platelets, mac- 
rophages, and leucocytes were see” in radiated arteries not completely covered by 
endothelial cells. 
1 month 3 months 6 months 
Endothelialized surface 
Control 92 * 4% 95 * 2%, 96 f 2% 
15Gy 37 * 4%’ 32 f 12%’ 40 * 8%’ 
30 Gy 37 * 8%’ 29 * 13%’ 35 * 12%. 
lntimal area. mm2 
Control 0.86 * 0.21 1 .Ol * 0.11 1.28 -t 0.26 
15Gy 0.80 r 0.42 0.66 * 0.07’ 1.35 + 0.37 
30 Gy 0.57 * 0.27 0.66 * 0.04’ 0.75 * 0.09 
* pco.05 versus c0ntrOl 
Conclusions: Re-endothelialization after VBT IS not completed at 6 months after VBT. 
Thus, special cars with prolonged antiplatelet therapy should be considered beyond this 
time point. 
1128-182 Multi-Center Experience With a Novel ir”’ Vascular 
Brachytherapy Device for In-Stent Restenosis: Final 
Results of the Angiorad Radiation Therapy for In- 
Stent Restenosis lntracoronaries II (ARTISTIC II) Trial 
Dean J. Kereiakes. Ron Waksman, Anilkumar Mehra, Carlos E. Morales, Ray Magorien, 
Melissa Mazzoni, Jeffrey J. Popma, The Lindner Center/Ohio Heart Health Center, 
Cincinnati, OH 
Background: Although vascular brachytherapy (VBT) reduces restenosis (RES) and 
major adverse cardiovascular events (MACE) after therapy for in-stent restenosis (ISR), 
both dose (Gy) and VBT catheter profile limit efficacy of currently available devices. 
Methods: A novel 0.0136’ lr’= sourcewire (AngioRadTM, Interventional Therapies, LLC, 
Westport, CT) and a 0.032” proflle delivery catheter/centering balloon (6 Fr guide cathe- 
ter compatible), which provides 18 Gy at 2 mm from the source center, was used to treat 
236 patients (age 62 years; 64% male; 38% diabetes) with ISR at 11 U.S. centers. His- 
torical controls (no VBT) were derived from the following randomized trials: ARTISTIC I 
(“=54) randomized trial and the Washington Radiation for In-stent Restenosis Trial 
(WRIST; n=50). Quantitatw coronary angiography was performed periprocedurally and 
at 6 months; clinical follow-up evaluation was at 30 days and 6 months. 
PRE PROCEDURE 
RVD mm (SD) 
Lesion Length mm (SD) 
lr192 (n=236) Control (n=104) 
2.71 (0.5)‘” 2.55 (0.4) 
14.36 (7.0)” 18.74 (8.4) 
POSTPROCEDURE 
MLD mm (SD) 
% stenosis 
Total MACE’ (30 day) 
1.93 (0.4)” 1.84 (0.4) 
28.9%* 11.5%** 28.7% _+ 11.7% 
2.1% 1.9% 
RVD = reference vessel diameter: MLD = minimum lumen diameter; 
lVR = target vessel revascularization; TSR = target site revascularization 
‘Death, myocardial infarction, emergent CABG or TLR 
*‘73% data complete analysis at submission 
1128-185 Late Stent Melapposition After Brachytherapy: An 
Assessment of the Incidence and Mechanisms Using 
Volumetric Intravascular Ultrasound 
Conclusions: Low profile and delwerability of this novel Ir’g’system facilitate VBT use. 
Effectiveness of the Angiorad TM, System is supported by low 30 day MACE, limited late 
loss and infrequent restenosis. Completed angiographic and clinical follow-up will be pre- 
sented. 
Jerzv Preaowski Lukasz Kallnczuk, Gary S. Mintz, Christian E. Dilcher. Rosanna C. 
Ghan, Jun-ichi Kotani, Vivek Shah, Ron Waksman, Neil J. Weissman, Washington 
Hospital Center, Washington, DC 
1128-183 Prolonged Antiplatelet Therapy After Coronary 
Brachytherapy: When Is It Safe to Stop Clopidogrel? 
Late stent malapposition (LSM) is a potential complication of intracoronary brachyther- 
spy (BT). We evaluated the incidence and mechanism of LSM after gamma-BT (lr-192) 
in 238 patients with in-stent restenosis (ISR) enrolled in the WRIST. Long WRIST. 
WRIST-PLUS, Gamma-l and ARTISTIC trials. Planar and volumetric IVUS analyses was 
performed every lmm within the malapposed segment as well as within 5mm long “con- 
troI” seaments with comr+ete circumferential aooosition: external elastic membrane 
enosis. Patients who did not receive a new stent were treated with cloprdogrel for a mini- 
mum of 6 months. Patients who required a new stent at the time of brachyiherapy 
received clopidorgel for at least 12 months. 
Results: Of 492 patients enrolled, only 22.7% required new stents. Mean follow-up was 
421.9 +148.4 days. Clopidogrel had been discontinued for >6 months in only 
67(13,6%)patie”ts (Table). Three patients sustained subacute thrombosis prior to 30 
days. All three patients had received new stents during their index procedure. There was 
one late thrombosis at 20 months (0.2%) in a patient who did not receive a new stent and 
who completed a six-month ccwrse of clopidogrel. 
Conclusions: A stragedy of avoiding new stem implantation and prolonged adjunctive 
antlplatelet is associated with a very low risk of late thrombosis (0.2%). The zealous use 
of off-protocol clopidogrel makes it difficult to determine the optimal duration of anti-plate- 
let therapy, particularly in patients receiving new stents. Until further data is obtained we 
recommend indefinite clopidogrel therapy after intra-coronary brachytherapy in patients 
receiving new stents. 
Table 1 
Plavix Dicontinued New Stent No New Stent 
>l Month 175 35 
>3 Months 58 29 
>6 Months 42 25 
1128-184 Longer Sources of lntracoronary Brachytherapy for In- 
Stent Restenosis Reduces Restenosis in the Real World 
Annapooma S. Kim, Ajay Agarwal, Shazia Mukaddam, Mary E. Duffy, Michael C. Kim, 
Mazullah Kamran. Warren Sherman, Samin K. Sharma, The Mount Sinai Medical 
Center, New York, NY 
Background: The major concern from randomized intracoronary brachytherapy (ICBT) 
trials was edge restenosis due to use of short source. Target lesion revascularization 
(TLR) with use of longer ICBT swrces has not been studied. 
Methods: We analyzed 150 consecutive patients with in-stent restenosis (170 vessels 
and 182 lesions) who had cutting balloon (CB PTCA) and/or rotational atherectomv fol- 
lowed by beta radiation using the Novoste system (30 mm source in 114 and 4d mm 
swrce in 68 lesions) and followed for mea” 6+3 months. 
Results: Mean age was 64+11 years, male sex 67%, CCS class III-IV 26%, z-1 prior res- 
tenosis 50%, restenosis interval 162+52 days. Periprocedural CK-MB elevation occurred 
in 15.8% patients, average in-hospital stay was 2.1e2.8 days, GP llbillla use 65%. Plavix 
was recommended for l-6 months. At follow-up: TVR 9.3% (14 pts, 11 TLR, and 3 “on- 
TLR), delayed acute closure/subacute thrombosis 0%. death 2.7% (1 in-hospital, 3 at fol- 
low-up). 
Table of Contents 
2 Procedural Characteristics & QCA 
Procedural Characteristics & QCA 
Lesion length (mm) 17.5+8.9 Ref. vessel size (mm) 2.91*0.04 
LADILCWRCAI(%) 44/28/21 MLD-Pre (mm) 0.72+0.31 
Total occlusion 10% MLD-Post (mm) 2.21iO.42 
CB PTCA+Rotablator 65% MLD-Post ICBT (mm) 2.12eO.32 
Rotablator 30% Re-dilatation post ICBT 5% 
Re-stem 3.3% Vessel spasm 4% 
Conclusion: Debulking followed by ICBT provides sustained long-term, acceptable rest- 
enosis in single digits. Compared to randomized trials, these favorable results in the real 
world are perhaps due to better understanding of the restenotic process after ICBT and 
represent the benefit of full lesion coverage by long source, leaving moderate residual 
stenosis and very low need for restenting. 
Antonio P. Madrid, Mark A. Grise, Jeffrey W. Moses, Martin B. Leon, Peter J. Casterella, (EEM), <tent, intra-stent ‘lumen, LSM, effective’ iurne” (intrastent lumen+LSM), and 
Anca Tchelibi, Cristia” Cioar. Huan Giap. Shirish Jani, Steven Baker, Prabhakar plaque (EEM minus effective lumen) area. Dose volume histograms (DVH) were calcu- 
Tripuraneni. Alexandra Lansky, Manuela Negoita, Roxanna Mehran, Paul S. Teirstein, lated for LSM segment, the wall of the vessel with complete apposition opposite the arc 
Scripps Clinic. La Jolla, CA, Lenox Hill, New York, NY of LSM, and the control segments. Results: There were 111152 LSM in the irradiated 
Background: The objective of SCRIPPS Ill study was to evaluate the impact of both 
group (7.2%) vs only 2/86 in the placebo (2.3%. p=O.14). 8 LSM occurred within old 
extended antiplatelet therapy and reduced stenting on late target thrombosis following 
stents and 5 in newly placed stents. 
brachytherapy. 
The length and volume of malapposition were 4.82* 7.44mm and 9.52*10.31mm3. LSM 
Methods: At two centers (Scripps Clinic and Lenax Hill) attempts were made to avoid 
segments underwent vessel enlargement that was greater than the increase in plaque 
new Stent implantation at the time of intracoronary radiation for treatment of in-stem rest- 
while control segments showed no change in EEM or plaque. DVH calculations were 
similar for LSM and control segments. 
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Conclusions: In ISR lesions, LSM lends to occur more often with BT than without BT. The 
mechanism is usually an increase in EEM (positive remodeling) greater than the increase 
in plaque. 
Baseline (mm2) Follow-up(mm2) P 
Mean EEM 20.464.62 
Mean Intra-stent lumen 6.96k1.46 
Mean Stent 6.69t1.69 
Mean Plaque 11.75*3.79 







Mean EEM 19.92*4.34 20.95*5.06 0.246 
Mean Lumen 7.05tl.54 6.4&i .15 0.091 
Mean Stem 6.49e1.67 6.26e1.55 0.424 
Mean Plaque 11.43zt2.97 12.66 23.96 0.155 
1128-186 Two-Year Clinical Follow-Up of lntracoronary Radiation 
Therapy Using 188Re-DTPA-Filled Balloon System After 
Coronary Artery Stenting 
Youna-Seek Cho, Bon-Kwon Koo, In-Ho Chae, Myoung-Mook Lee, Young-Bae Park, 
Seoul National University, Seoul, South Korea 
Background: Intra-coronary beta radiation therapies are known to reduce restenosis rate 
after coronary angioplasty, but late effects of these procedures are uncertain. The objec- 
tive of this study is to evaluate the long-term effect on clinical outcome of 166Re-DTPA- 
filled balloon system following coronary artery stenting. 
Methods: One-hundred twenty-two patients with significant de now or in-stent restenosis 
lesions were recruited in this prospective, randomized. case-controlled study and fol- 
lowed-up for 34.0 f 6.6 months. 64 patients were randomized to 166Re group and 56 to 
control group. 
Results: There were no significant differences in clinical diagnosis, cardiovascular risk 
factors, and angiographic lesion characteristics between two groups. At two-year clinical 
follow-up, target-vessel revascularization rate (TVR) was significantly lower in 166Re 
group (14.1% vsrsus 29.3%: P = 0.040) than control group, maintaining early benefit 
observed at 6-months (10.9% in 166Re group versus 27.6% in control; P = 0.019). Two 
patients in 166Re group (at 16-months and 24-months follow-up, respectively) and one in 
control group (at 34 months) received a new TVR after 6.months follow-up. There were 
one non-fatal myocardial infarction in 166Re group at 19.months, and no cardiac death 
after 6-months. The composite end point of cardiac death, non-fatal MI, or TVR at two- 
years follow-up period did not show significant difference between both groups (15.6% in 
166Re versw 29.3% in control; P = 0.069), although it had been significantly lower in 
166Re group by 6-months (29.3% versus 12.5%; P = 0.022). 
Conclusion: Long-term outcomes of intracoronary radiation therapy with 166Re-DTPA- 
filled balloon after coronary artery stenting were favorable with a low rate of NR, 
although some late failures were observed. 
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1129-173 Low Stroke Rates During Carotid Artery Stenting With 
Neuroprotection 
Gishel New, Gary S. Roubin, Sriram S. lyer, Roxana Mehran. Yuliya G. Adamyan. 
Christina Brennan, George Dangas, Monica Losquadro, Michael Guiry, Palawi Kumar. 
Jiri J. Vitek. Lenox Hill Heart and Vascular Institute. Cardiovascular Research 
Foundation, New York, NY 
Background: Neuroprotection devices are used during carotid stenting to eliminate dis- 
tal embolic debris and subsequent neurologic complications. 
Methods: We report results after carotid artery stenting using a variety of distal protec- 
tion devices in 376 patients (397arteries) [(MednovaTM, n=69, AngioguardTM, n=6, Accu- 
netTM, n=4) a distal balloon occlusion catheter (PercusurgeGuardwireTM, 11~266) or a 
proximal balloon occlusion catheter (ParodiTM. n=lO)]. Devices were chosen on the basis 
of intracranial collateral circulation, “high-risk” features and eligibility criteria for specific 
protocols. All patients had a NIH Stroke Scale performed before and within 24 hours after 
the procedure. 
Results: The mean age was 73 f 10 years. 14% had a history of stroke, amaurosis 
fugax in 6% and 30%, had a history of TIA within the past B-months, 13% had a prior 
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CEA. 11% had prior neck radiation or surgery, 46% had bilateral disease and 9% had a 
contralateral occlusion. Procedural success @tent placement and no complication) was 
achieved in 96.7%. 
Thirty-Day Outcomes All pts Balloon Filter P-Value 
N= patients/arteries 378/397 2791296 99/101 NS 
Minor Stroke 4 (1.2%) 3 (1.0%) 1 (1.0%) NS 
Major Stroke 1 (0.3%) 1 (0.3%) 0 NS 
Retinal Embolus 4(1.0%) 3(1.0%) l(l.O%) NS 
Stroke Related Death 1(0.3%) 1 (0.3%) 0 NS 
Non-Stroke Related Death 2 (0.6%) 2 (0.6%) 0 NS 
All Strokes and Deaths 8 (2.2%) 7 (2.3%) 1 (1.0%) NS 
All Strokes 6 (1.5%) 5 (1.7%) 1 (1.0%) NS 
There were no differences in outcomes between filters or balloon occlusion devices. The 
only multivariate predictor of stroke was a contralateral occlusion. 
Conclusion: Neuroprotection during carotid stenting is associated with low neurologic 
complication of any type (embolic or other) without any differnce between balloon occlu- 
sion or filters. These data support the use of these devices in all carotid stsnting proce- 
dures. 
1129-174 The Volume of Embolic Particles Retrieved via Distal 
Protection Is Similar With Either Occlusion Balloon or 
Filter, but Markedly Lower in Carotid Arterial Than 
Saphenous Vein Grafl Interventions 
Arun Kuchsla Andrew C. Eisenhauer, Rany Huynh. Bernard Chevalier, Joachim 
Schafer, Philip A. Seifelt, Natalie D. Macon, Campbell Rogers, Brigham B Women’s 
Hospital, Boston, MA, Massachusetts Institute of Technology, Cambridge, MA 
Objective: Characterize particulate retrieved from carotid artery interventions (CAI) and 
aorto-coronary saphenous vein graft interventions (SVGI) either via a distal occlusion 
balloon or an embolic protection filter. 
MethodeiResults: Particulate from 3 CAI and 17 SVGI using embolic occlusion balloon 
protection (Percusurge, Medtronic/AVE) and 5 CAI and 47 SVGI using a braided nitinol 
filter (Medtronic AVE) was analyzed for particle size and aggregate embolic volume 
using an automated computer imaging system (Rapidwe, Beckman Couiter). The parti- 
cle size distribution for all groups was nearly identical, with the majority being < 96 pm in 
longest dimension (Figure). The embolic volumes for CAI (2.79 mm3 for balloon, 2.72 
mm3 for filter) were significantly smaller than for SVGI. using either a balloon or filter (16 
mm3 for both). Histologic evaluation revealed similar composition. 
Conclusion: Aggregate embolic volumes for similar interventions are equivalent regard- 
less of whether balloon occlusion or filter protection is employed. However, CAI yield only 
approximately 20% of the embolic volume of SVGI, with similar size distributions. Either 
SVG lesions provide a larger embolic load, or carotid lesions are prone to incomplete 
capture due to loss up the external carotid artery. 
1129-175 Carotid Artery Stenting Can Be Safely Performed in 
Elderly Patients: A Single Center Experience 
John P. Reilly, Hugo Quintana, Tyrone J. Collins, James S. Jenkins, Stephen R. Ramee, 
Christopher J. White, Ochsner Clinic, New Orleans, LA 
Background: Carotid artery stenting (CAS) is an accepted treatment for carotid artery 
disease, and is particularly attractive in patients at high risk for surgical endarterectomy. 
Previous reports suggest that elderly patients are at high risk for significant complications 
during CAS. 
Methods: A prospective database of all patients undergoing CAS at our institution was 
interrogated. All patients over 60 years old were evaluated. We reviewed hospital and 
outpatient records of all patients to confirm and complete the database. The primary end- 
points evaluated were neurologic events during the hospitalization and at 30 days. 
Results: Glpatients over 80 years old underwent 65 CAS procedures at our institution 
since July 1994. The mean age was 62.62 2.6 years (range 60 - 95 years). 32 CAS pro- 
cedures were performed on the right carotid ariery and 33 on the left carotid artery. The 
mean stenosis was 90.6% -+ 6.9%. There were 15 diabetics, 12 smokers, 39 hyperten- 
sives and 33 with hypercholesterolemia. Eighteen patients had previously undergone 
coronary bypass surgery, and nine had previously undergone carotid endalterectomy. 
Ten patients had a prior myocardial infarction. Twenty-five patients were asymptomatic. 
In-hospital event rates for 61 CAS procedures (93.6%) were obtained. and follow-up at 
30 days was available for 39 CAS procedures (60.0%). Two patients (3.6%) had events 
during the initial hospitalization, which were classified as minor strokes by a neurologist. 
